| Product dosage: 0.03mg | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 1 | $53.15 | $53.15 (0%) | 🛒 Add to cart |
| 2 | $50.64 | $106.29 $101.28 (5%) | 🛒 Add to cart |
| 3 | $50.14 | $159.44 $150.41 (6%) | 🛒 Add to cart |
| 4 | $49.89 | $212.58 $199.55 (6%) | 🛒 Add to cart |
| 5 | $49.54 | $265.73 $247.68 (7%) | 🛒 Add to cart |
| 6 | $49.47 | $318.87 $296.81 (7%) | 🛒 Add to cart |
| 7 | $49.28 | $372.02 $344.94 (7%) | 🛒 Add to cart |
| 8 | $49.26 | $425.16 $394.08 (7%) | 🛒 Add to cart |
| 9 | $49.25 | $478.31 $443.21 (7%) | 🛒 Add to cart |
| 10 | $49.13
Best per bottle | $531.46 $491.35 (8%) | 🛒 Add to cart |
Synonyms | |||
More info:
Acamprol 333 mg: Restoring Neurochemical Balance in Alcohol Dependence
Acamprol 333 mg is a specialized pharmacological agent indicated for the maintenance of abstinence in alcohol-dependent patients. Its unique formulation targets key neurotransmitter systems implicated in alcohol craving and withdrawal, offering a non-habit-forming, evidence-based approach to support recovery. By modulating glutamatergic hyperactivity and balancing inhibitory pathways, Acamprol helps reduce the psychological and physiological drive to consume alcohol, making it a cornerstone in comprehensive treatment plans under medical supervision. Features Contains 333 mg of calcium acetylhomotaurinate per enteric-coated tablet Delayed-release formulation for optimal gastrointestinal tolerance Does not undergo hepatic metabolism; eliminated renally unchanged Non-sedating with minimal abuse potential Compatible with most psychosocial interventions Requires no titration to therapeutic dose in patients with normal renal function Benefits Reduces craving intensity and frequency in alcohol-dependent individuals Helps maintain abstinence by decreasing relapse risk Minimizes withdrawal-related anxiety and discomfort Supports cognitive function restoration during early recovery Does not produce euphoria or dependence Compatible with long-term maintenance therapy Common use Acamprol 333 mg is primarily prescribed for alcohol dependence treatment in patients who have achieved initial abstinence.
Acamprol: Clinically Proven Relief for Alcohol Dependence
Acamprol (acamprosate calcium) is a prescription medication specifically formulated to support the maintenance of abstinence in alcohol-dependent patients who have achieved initial withdrawal and are committed to a comprehensive treatment program. It functions by helping to restore the natural balance of neurotransmitters in the brain, which are often disrupted by chronic alcohol use. By mitigating the neuronal hyperexcitability associated with alcohol withdrawal and craving, Acamprol provides a pharmacological foundation upon which behavioral therapy and counseling can build greater efficacy.
Acamprol: Clinically Proven Support for Alcohol Dependence Recovery
Acamprol (acamprosate calcium) is a prescription medication specifically developed to support maintenance of abstinence in alcohol-dependent patients who have achieved initial withdrawal. As a non-opioid, non-aversive pharmacological agent, it works by helping restore the disrupted neurotransmitter balance in the brain caused by chronic alcohol consumption. Clinical studies demonstrate its efficacy in reducing relapse rates when used as part of a comprehensive treatment program that includes psychosocial support. This neurostabilizer represents a cornerstone in modern addiction medicine, offering physiological support for the challenging process of long-term recovery.
Anabuse: The Clinically Proven Alcohol Deterrent Therapy
Anabuse (disulfiram) is a prescription medication designed to support the treatment of chronic alcoholism by producing an acute sensitivity to ethanol. When taken as directed, it acts as a powerful psychological and physiological deterrent against alcohol consumption, helping individuals maintain sobriety as part of a comprehensive management plan that includes counseling and social support. Its mechanism is well-established, creating an unpleasant reaction if alcohol is ingested, thereby reinforcing commitment to abstinence.
Antabuse Generic: Clinically Proven Alcohol Dependence Management
Antabuse generic, containing the active ingredient disulfiram, is a cornerstone pharmacological intervention in the management of chronic alcohol dependence. It functions as an aversive agent, creating a highly unpleasant physiological reaction upon alcohol consumption, thereby supporting patient commitment to abstinence. This medication is prescribed as part of a comprehensive treatment plan that includes counseling and psychosocial support. Its efficacy is well-documented in clinical literature, offering a structured deterrent for individuals striving for long-term sobriety.
Antabuse Side Effects: Managing Disulfiram Therapy Safely
Antabuse (disulfiram) is a prescription medication used as an aversive therapy in the management of chronic alcoholism. When taken as directed, it creates a physiological response to alcohol consumption that serves as a powerful deterrent. Understanding the side effects, precautions, and proper usage of Antabuse is essential for both patients and healthcare providers to ensure safe and effective treatment outcomes. This comprehensive guide provides detailed medical information about Antabuse therapy, its mechanisms, and important safety considerations.
Antabuse: A Clinically Proven Deterrent for Alcohol Dependence
Antabuse (disulfiram) is a prescription medication used as an adjunct in the management of chronic alcohol dependence. It supports abstinence by producing a highly unpleasant physiological reaction if alcohol is consumed, thereby creating a powerful psychological deterrent. This medication is intended for use within a comprehensive treatment program that includes counseling and support. Proper medical supervision is essential to ensure safe and effective use. Features Contains disulfiram as the active pharmaceutical ingredient Available in 250 mg and 500 mg oral tablets Works by inhibiting the enzyme aldehyde dehydrogenase Causes accumulation of acetaldehyde if alcohol is consumed Requires daily administration to maintain effect Prescription-only medication requiring medical oversight Benefits Creates a strong psychological barrier against alcohol consumption Supports long-term abstinence when combined with behavioral therapy Provides a concrete mechanism to resist cravings and impulses Helps establish new patterns of behavior around alcohol use Reduces relapse rates when used as part of comprehensive treatment Empowers patients with a tangible tool for recovery management Common use Antabuse is primarily prescribed for individuals with diagnosed alcohol use disorder who are committed to maintaining abstinence.
Antabuse: A Clinically Proven Deterrent for Alcohol Use Disorder
Antabuse (disulfiram) represents a cornerstone of pharmacological aversion therapy in the treatment of chronic alcohol use disorder (AUD). It is not a cure for alcoholism, nor does it diminish the craving for alcohol. Instead, it acts as a powerful psychological and physiological deterrent by producing a highly unpleasant reaction when alcohol is consumed. This mechanism supports a patient’s commitment to abstinence by creating a significant negative reinforcement, allowing them to focus on the behavioral and psychosocial aspects of recovery within a comprehensive treatment plan.
Disulfiram Reaction: A Critical Safety Mechanism for Alcohol Dependence
The disulfiram reaction is a clinically significant, intentionally provoked adverse event resulting from the interaction between disulfiram medication and ethanol. This reaction is the cornerstone of the pharmacological deterrent therapy for chronic alcohol use disorder, designed to create a powerful psychological aversion to alcohol consumption. Its efficacy relies on a well-understood biochemical mechanism that produces highly unpleasant physical symptoms upon alcohol ingestion, thereby supporting long-term sobriety goals. This product card details the essential medical information surrounding this therapeutic reaction for healthcare professionals managing patients on disulfiram therapy.